Highlights {#Sec1}
==========

IC combined with CCRT significantly improved the survival outcomes of patients with locoregional advanced NPC.IC combined with CCRT showed higher relative risks of grade 3 or more neutropenia, thrombocytopenia, nausea, vomiting and hepatotoxicity throughout the course of treatment, and higher relative risks of grade 3 or more thrombocytopenia and vomiting during CCRT.

Background {#Sec2}
==========

Nasopharyngeal carcinoma (NPC) is one of head and neck tumors with an unbalanced endemic distribution and a high prevalence in Southeast Asia, Southeast China, and North Africa \[[@CR1]\]. More than two decades ago, locoregionally advanced NPC had an unfavorable prognosis. Since the administration of concurrent chemoradiotherapy (CCRT), the survival outcomes have been significantly improved \[[@CR2], [@CR3]\].

However, there are still over 20% of patients with locoregionally advanced NPC living for less than 5 years \[[@CR3]\]. In the European Society for Medical Oncology (ESMO) clinical practice guideline, CCRT is suggested to treat locoregionally advanced NPC (category 1A), while induction chemotherapy (IC) combined with CCRT is recommended to stage IV NPC patients (category 2B) \[[@CR4]\]. Nevertheless, this guideline has not been updated since 2012.

In the National Comprehensive Cancer Network (NCCN) clinical practice guideline for patients with locoregionally advanced NPC, the preferred recommendation is participating in clinical trials, while the category 2A and 2B recommendations are, respectively, IC followed by CCRT and CCRT alone \[[@CR5]\].

In the past decade, considerable studies on IC for NPC have been carried out. Among these clinical trials, different chemotherapeutic drugs and different doses or cycles of the IC were administered. However, owing to multiple clinical trials showing different results, adding IC to CCRT remains controversial.

Accordingly, in this systematic review and meta-analysis, we compared the IC plus CCRT with CCRT alone in NPC patients to analyze the 3-year/5-year survival outcomes and grade ≥ 3 toxicities in the registered and prospective clinical studies.

Methods {#Sec3}
=======

This analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline (PRISMA) \[[@CR6]\].

Search strategy {#Sec4}
---------------

A systematic literature search was performed in PubMed, EMBASE, Web of Science, and Cochrane Library databases to identify all relevant records up to Sep 11, 2019. Search terms included: "induction chemotherapy", "concurrent chemoradiotherapy", "nasopharyngeal carcinoma", and "randomized controlled trial or randomized clinical trial or clinical trial or trial". The references of relevant articles were manually searched for more clinical studies. The search records were uploaded into EndNote software (<http://endnote.com/>) for further review.

Selection criteria {#Sec5}
------------------

All of the eligible clinical trials should meet the following inclusion criteria: (1) prospective studies in previously untreated patients with NPC, (2) all eligible studies were registered clinical trials and provided the registered numbers, (3) only randomized controlled clinical studies were eligible, (4) in randomized controlled studies, the experiment group was treated with IC combined with CCRT, and the control group was treated with CCRT alone, (5) neoadjuvant chemotherapy described in the articles was deemed as induction chemotherapy, (6) IC or CCRT combined with target therapy was excluded, (7) because of the absence of complete efficacy and safety data, conference abstracts were excluded, (8) studies were published in English. Any disagreements were resolved by discussion.

Data extraction and quality assessment {#Sec6}
--------------------------------------

The primary outcome was overall survival (OS), failure-free survival (FFS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRFS), and the second outcome was toxicity. FFS was defined as the date of randomization to documented disease progression (the date of locoregional/distant failure or death from any cause, whichever occurred first). Two authors (BW and BX) independently extracted information from the full texts and supplementary materials. Any discrepancies were resolved by consensus. The following details were extracted from each eligible clinical trial: first author, publication year, inclusion period, registered number, study design, number of patients, mean age, median follow-up, therapeutic regimens, OS, FFS, DMFS, LRFS, survival rate, and adverse events. The Jadad scoring scale was used to evaluate the methodological quality of each eligible trial by two authors (BW and BX) \[[@CR7]\].

Statistical analysis {#Sec7}
--------------------

Survival outcomes (OS, FFS, DMFS and LRFS) from randomized controlled studies were assessed by hazard ratio (HR) with 95% confidence interval (CI) using Cochrane Collaboration's Information Management System (RevMan) software (version 5.3). Toxicities were calculated as risk ratios (RRs) and 95% CIs. The chi-squared (χ^2^) tests and *I*^2^ statistic percentages were used to test and quantify the heterogeneity. A fixed-effects model (Mantel-Haenszel method) was adopted in the calculations if *I*^2^ ≤ 50%, otherwise, a random-effect model was applied. When *p* \< 0.05, the differences were considered statistically significant.

Results {#Sec8}
=======

Eligible studies and characteristics {#Sec9}
------------------------------------

Our search of the PubMed, EMBASE, Web of Science, and Cochrane Library databases identified 524 relevant publications. Two additional records were identified through reference lists. 167 duplicated records were removed. After screening the titles and abstracts, 195 records were excluded. After eligibility assessment, a total of nine studies were selected for inclusion in the systematic review, comprising seven randomized controlled studies (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8]--[@CR16]\]. Table [1](#Tab1){ref-type="table"} showed the basic characteristics of the eligible clinical trials. Table [2](#Tab2){ref-type="table"} displayed the details of therapeutic regimens and rates of OS, FFS, objective response, and grade ≥ 3 toxicities in the selected studies. Fig. 1Flow chart of the selection processTable 1Characteristics of the eligible studiesStudyYearInclusion periodRegisterRegion/ CountryPhaseGroupNo.patientsNo.maleMean Age (range, year)StageAJCCMedian follow-up (years)Jadad scoreFountzilas \[[@CR8]\]20122003--2008ACTRN12609000730202EuropeIIIC + CCRTCCRT7269554849 (19--82)51 (15--79)IIb-IVb6th4.64Tan \[[@CR9]\]20152004--2012CDR0000657121SingaporeII/IIIIC + CCRTCCRT8686716349 (42--55)52 (44--57)III-IVb5th3.43.23Sun \[[@CR10]\]/Li \[[@CR11]\]2016/20192011--2013NCT01245959ChinaIIIIC + CCRTCCRT24123919317442 (36--49)44 (39--50)III-IVb7th63Cao \[[@CR12]\]/Yang \[[@CR13]\]2017/20192008--2015NCT00705627ChinaIIIIC + CCRTCCRT23823817319044 (19--65)42 (21--66)III-IVb6th6.93Frikha \[[@CR14]\]20182009--2012NCT00828386France/ TunisiaIIIIC + CCRTCCRT424128324648T2b, T3, T4 and/or N1-N3, M0NR3.63Hong \[[@CR15]\]20182003--2009NCT00201396ChinaIIIIC + CCRTCCRT23924017617945 (15--69)47 (19--70)IVa-IVb5th63Zhang \[[@CR16]\]20192013--2016NCT01872962ChinaIIIIC + CCRTCCRT24223818216446 (18--64)45 (20--64)III-IVb7th3.63*IC* induction chemotherapy; *CCRT* concurrent chemoradiotherapy; *AJCC* American Joint Cancer Committee; *NR* not reportedTable 2Therapeutic regimens, survival outcomes and toxicities in eligible studiesStudyInduction chemotherapyRadiotherapyConcurrent chemotherapyIC + CCRT\|CCRTOS rateFFS rateDMFS rateLRFS rateORRGrade ≥ 3 AE rateFountzilas 2012 \[[@CR8]\]Epi 75 mg/m^2^, Pac 175 mg/m^2^ and DDP 75 mg/m^2^ every 21 days for 3 cycles2D-CRT, 3D-CRTDDP 40 mg/m^2^ every week3-year: 66.6%*\|*71.8%3-year: 64.5%*\|*63.5%FEFE83%*\|*85%FETan 2015 \[[@CR9]\]Gem 1000 mg/m^2^, CBP area under the concentration-time-curve 2.5, and Pac 70 mg/m^2^ (day 1 and 8) every 21 days for 3 cycles2D-CRT, IMRTDDP 40 mg/m^2^ every week3-year: 94.3%*\|*92.3%3-year: 74.9%\|67.4%3-year: 83.8%\|79.9%FEFE52%*\|*37%^b^Sun/Li 2016/2019 \[[@CR10]\] \[[@CR11]\]Doc 60 mg/m^2^, DDP 60 mg/m^2^ and 5-FU 600 mg/m^2^ every 21 days for 3 cyclesIMRTDDP 100 mg/m^2^ every 21 days for 3 cycles3-year: 92.1%*\|*86.2%;5-year: 85.6%*\|*77.7%3-year: 80.1%*\|*72.0%;5-year: 77.4%*\|*66.4%3-year: 88.8%*\|*82.0%;5-year: 88.0%*\|*79.8%^b^3-year: 91.7%*\|*87.4%;5-year: 90.7%*\|*83.8%^b^98.8%*\|*100%72.8%*\|*53.8%Cao/Yang 2017/2019 \[[@CR12]\] \[[@CR13]\]DDP 80 mg/m^2^ and 5-FU 800 mg/m^2^ (day 1--5) every 21 days for 2 cycles2D-CRT, IMRTDDP 80 mg/m^2^ every 21 days for 3 cycles3-year: 88.2%*\|*88.5%; 5-year: 80.8%*\|*76.8%^b^3-year: 82.0%*\|*74.1%; 5-year: 73.4%*\|*63.1%^b^3-year: 86.0%*\|*82.0%; 5-year: 82.8%*\|*73.1%^b^3-year: 94.3%*\|*90.8%; 5-year: 87.9%*\|*85.0%98.7%*\|*99.2%66.3%\|49.1%^ab^Frikha 2018 \[[@CR14]\]Doc 75 mg/m^2^, DDP 75 mg/m^2^ and 5-FU 750 mg/m^2^/day day (1--5) every 21 days for 3 cyclesIMRT, non-IMRTDDP 40 mg/m^2^ every week3-year: 86.3%*\|*68.9%3-year: 73.9%*\|*57.2%FEFEFEFEHong 2018 \[[@CR15]\]Mit 8 mg/m^2^, Epi 60 mg/m^2^, and DDP 60 mg/m^2^ on day 1, 5-FU 450 mg/m^2^ and Leu 30 mg/m^2^ on day 83D-CRT, IMRTDDP 30 mg/m^2^ every week5-year: 72.0%*\|*67.9%5-year: 61.1%*\|*50.0%5-year: 76.2%*\|*70.8%5-year: 79.9%*\|*70.0%95.3%\|92.5%FEZhang 2019 \[[@CR16]\]Gem 1 g/m^2^ (day 1 and 8) and DDP 80 mg/m^2^ every 21 days for 3 cyclesIMRTDDP 100 mg/m^2^ every 21 days for 3 cycles3-year: 94.6%*\|*90.3%3-year: 85.3%*\|*76.5%3-year: 91.1%*\|*84.4%3-year: 91.8%*\|*91.0%97.9%*\|*98.7%75.7%*\|*55.7%epirubicin: Epi; paclitaxel: Pac; cisplatin: DDP; gemcitabine: Gem; carboplatin: CBP; docetaxel: Doc; 5-fluorouracil: 5-FU; mitomycin: Mit; leucovorin: Leu; 2D/2D-CRT: 2/3-dimensional conformal radiotherapy; *IMRT* intensity modulated radiotherapy; *OS* overall survival; *FFS* failure-free survival; *DMFS* distant metastasis-free survival; *LRFS* locoregional relapse-free survival; *ORR* objective response rate; *AE* adverse event; *FE* fail to extract^a^ AE during concurrent chemotherapy^b^ means statistically significant

Across the eligible studies, Zhang et al showed the highest rates of 3-year survival outcomes for patients treated with IC plus CCRT (OS: 94.6% versus 90.3% in CCRT group; FFS: 85.3% versus 76.5% in CCRT group). In Frikha's study, the IC + CCRT group had the greatest improvements in 3-year survival rates compared with CCRT group (OS: 86.3% versus 68.9%; FFS: 73.9% versus 57.2%). In the setting of 5-year survival data, Yang et al exhibited that IC plus CCRT significantly increased the efficacy against CCRT alone (OS: 80.8% versus 76.8%, *p* = 0.04; FFS: 73.4% versus 63.1%, *p* = 0.007). However, IC followed by CCRT had similar objective response rates (ORRs) compared to CCRT (e.g. Fountzilas' study: 83% versus 85%, *p* = 0.82; Cao's study: 98.7% versus 99.2%, *p* \> 0.05). For grade ≥ 3 adverse events, the rates in the IC + CCRT group ranged from 52.0 to 75.7%, which is significantly increased in comparison with the CCRT group (ranged from 37.0 to 55.7%).

Overall survival (OS) {#Sec10}
---------------------

3-year OS data were available from six randomized controlled trials with 1832 patients (IC + CCRT group: 921 patients; CCRT group: 911 patients). Forest plots showed patients obtained greater OS benefit from IC + CCRT compared with CCRT alone (HR: 0.70, 95% CI: 0.55--0.89, *p* = 0.003; H: *I*^2^ = 33%, *p* = 0.19) (Fig. [2](#Fig2){ref-type="fig"}a). Fig. 2Forest plots of hazard ratios for 3-year (**a**) and 5-year (**b**) overall survival in nasopharyngeal carcinoma

5-year OS data were available from three randomized controlled trials with 1435 patients (IC + CCRT group: 718 patients; CCRT group: 717 patients). Pooled results indicated that IC + CCRT led to significantly superior OS than CCRT (HR: 0.77, 95% CI: 0.62--0.94, *p* = 0.01; H: *I*^2^ = 12%, *p* = 0.32) (Fig. [2](#Fig2){ref-type="fig"}b).

Failure-free survival (FFS) {#Sec11}
---------------------------

3-year FFS data were extracted from six randomized controlled studies involving 1832 patients (IC + CCRT group: 921 patients; CCRT group: 911 patients). IC + CCRT appeared to show better FFS than CCRT (HR: 0.67, 95% CI: 0.55--0.80, *p* \< 0.0001; H: *I*^2^ = 34%, *p* = 0.18) (Fig. [3](#Fig3){ref-type="fig"}a). Fig. 3Forest plots of hazard ratios for 3-year (**a**) and 5-year (**b**) failure-free survival in nasopharyngeal carcinoma

5-year FFS data were extracted from three randomized controlled studies involving 1435 patients (IC + CCRT group: 718 patients; CCRT group: 717 patients). IC + CCRT exhibited significant FFS superiority compared with CCRT (HR: 0.70, 95% CI: 0.58--0.83, *p* \< 0.0001; H: *I*^2^ = 0%, *p* = 0.84) (Fig. [3](#Fig3){ref-type="fig"}b).

Distant metastasis-free survival (DMFS) {#Sec12}
---------------------------------------

The data of 3-year DMFS were available from five randomized controlled studies with 1691 patients (IC + CCRT group: 849 patients; CCRT group: 842 patients). The DMFS value was significantly prolonged for patients treated with IC + CCRT compared with CCRT (HR: 0.58, 95% CI: 0.45--0.74, *p* \< 0.0001; H: *I*^2^ = 0%, *p* = 0.72) (Fig. [4](#Fig4){ref-type="fig"}a). Fig. 4Forest plots of hazard ratios for 3-year (**a**) and 5-year (**b**) distant metastasis-free survival in nasopharyngeal carcinoma

5-year DMFS data were available from three randomized controlled studies with 1435 patients (IC + CCRT group: 718 patients; CCRT group: 717 patients). A significantly lower risk of distant metastasis was shown in the IC + CCRT group versus the CCRT group (HR: 0.69, 95% CI: 0.55--0.87, *p* = 0.001; H: *I*^2^ = 0%, *p* = 0.42) (Fig. [4](#Fig4){ref-type="fig"}b).

Locoregional relapse-free survival (LRFS) {#Sec13}
-----------------------------------------

3-year LRFS data were collected from four randomized controlled studies involving 1519 patients (IC + CCRT group: 763 patients; CCRT group: 756 patients). Consistent with the results for DMFS, patients receiving IC + CCRT appeared to exhibit better LRFS than those receiving CCRT (HR: 0.69, 95% CI: 0.50--0.95, *p* = 0.02; H: *I*^2^ = 0%, *p* = 0.70) (Fig. [5](#Fig5){ref-type="fig"}a). Fig. 5Forest plots of hazard ratios for 3-year (**a**) and 5-year (**b**) locoregional relapse-free survival in nasopharyngeal carcinoma

5-year LRFS data were collected from three randomized controlled studies involving 1435 patients (IC + CCRT group: 718 patients; CCRT group: 717 patients). The IC + CCRT group showed a statistically significant lower risk of locoregional relapse than the CCRT group (HR: 0.66, 95% CI: 0.51--0.86, *p* = 0.002; H: *I*^2^ = 0%, *p* = 0.80) (Fig. [5](#Fig5){ref-type="fig"}b).

Grade ≥ 3 toxicities {#Sec14}
--------------------

For grade 3 or more adverse events during the IC and CCRT, two randomized controlled trails compared the IC plus CCRT group against the CCRT group \[[@CR10], [@CR11], [@CR16]\]. In hematological toxicities, there were no significant differences in leukopenia (risk ratio \[RR\]: 1.77, 95% CI: 0.98--3.19, *p* = 0.06) and anemia (RR: 2.97, 95% CI: 0.20--44.40, *p* = 0.43) between IC + CCRT group and CCRT group. However, the IC + CCRT group showed significantly high risks of neutropenia (RR: 3.93, 95% CI: 1.78--8.68, *p* = 0.0007) and thrombocytopenia (RR: 6.55, 95% CI: 2.58--16.63, *p* \< 0.0001) than the CCRT group (Fig. [6](#Fig6){ref-type="fig"}a-d). In non-hematological toxicities, patients treated with IC + CCRT showed significantly higher risks of nausea (RR: 1.43, 95% CI: 1.09--1.87, *p* = 0.01), vomiting (RR: 1.40, 95% CI: 1.08--1.82, *p* = 0.01) and hepatotoxicity (RR: 5.37, 95% CI: 1.40--20.58, *p* = 0.01) rather than stomatitis (RR: 1.04, 95% CI: 0.87--1.24, *p* = 0.68) and dermatitis (RR: 0.73, 95% CI: 0.37--1.44, *p* = 0.37) in comparison with patients treated with CCRT (Fig. [6](#Fig6){ref-type="fig"}e-i). Fig. 6Forest plots of risk ratios for cumulative grade ≥ 3 hematological and non-hematological toxicities during overall treatment. (**a-d**) Cumulative grade ≥ 3 hematological toxicities (leukopenia (**a**), neutropenia (**b**), thrombocytopenia (**c**), and anemia (**d**)) during overall treatment. (**e-i**) cumulative grade ≥ 3 non-hematological toxicities (nausea (**e**), vomiting (**f**), hepatotoxicity (**g**), stomatitis (mucositis) (**h**), and dermatitis (**i**) during overall treatment

For grade ≥ 3 adverse events during the CCRT, in hematological toxicities, patients in IC + CCRT group showed significantly higher risks of thrombocytopenia (RR: 11.67, 95% CI: 2.46--55.34, *p* = 0.002) and anemia (RR: 3.81, 95% CI: 2.11--6.87, *p* \< 0.00001) than patients in CCRT group. There were no significant differences in leukopenia (RR: 1.41, 95% CI: 1.01--1.96, *p* = 0.05) and neutropenia (RR: 1.26, 95% CI: 0.68--2.34, *p* = 0.47) between IC + CCRT group and CCRT group (Fig. [7](#Fig7){ref-type="fig"}a-d). In non-hematological toxicities, patients treated with IC + CCRT showed a significantly higher risk of vomiting (RR: 0.62, 95% CI: 0.40--0.94, *p* = 0.03) rather than fatigue (RR: 1.52, 95% CI: 0.06--37.10, *p* = 0.80), nausea (RR: 1.44, 95% CI: 0.63--3.33, *p* = 0.39), stomatitis (mucositis) (RR: 0.88, 95% CI: 0.73--1.05, *p* = 0.16) and dermatitis (RR: 1.34, 95% CI: 0.20--9.04, *p* = 0.76) in comparison with patients treated with CCRT (Fig. [7](#Fig7){ref-type="fig"}e-i). Fig. 7Forest plots of risk ratios for grade ≥ 3 hematological and non-hematological toxicities during concurrent chemoradiotherapy. (**a-d**) Grade ≥ 3 hematological toxicities (leukopenia (**a**), neutropenia (**b**), thrombocytopenia (**c**), and anemia (**d**)) during concurrent chemoradiotherapy. (**e-i**) Grade ≥ 3 non-hematological toxicities (fatigue (**e**), nausea (**f**), vomiting (**g**), stomatitis (mucositis) (**h**), and dermatitis (**i**) during concurrent chemoradiotherapy

Publication bias {#Sec15}
----------------

Using the Jadad scoring scale, all enrolled trials were identified as high quality (a score of ≥3).

Discussion {#Sec16}
==========

In this meta-analysis, all survival data were significantly better in NPC patients treated with IC combined with CCRT than that in patients treated with CCRT alone.

We conducted this meta-analysis to estimate the efficacy and safety of IC combined with CCRT in NPC patients. There were several early meta-analyses indicating the benefits of IC in treating patients with locoregionally advanced NPC. However, most of the studies were published before 2018 (Table [3](#Tab3){ref-type="table"}) \[[@CR17]--[@CR21]\]. Song synthesized only four randomized clinical studies and demonstrated that IC followed CCRT performed significant treatment effects in DMFS and progression-free survival (PFS) rather than OS and LRFS \[[@CR18]\]. In a network meta-analysis conducted by Chen, the results showed that IC plus CCRT had a higher risk of locoregional recurrence than CCRT and found no significant improvement in OS \[[@CR17]\]. Tan analyzed six randomized controlled studies and five observation studies and displayed significant improvement in OS and PFS without the analyses of DMFS and LRFS \[[@CR21]\]. Moreover, the inclusion of retrospective studies might increase the bias of the analysis. Although Ouyang's pairwise meta-analysis confirmed the benefit in OS, PFS, DMFS and LRFS in NPC, patients in four of 10 included studies were treated with radiotherapy alone without concurrent chemotherapy \[[@CR19]\]. Thus, we considered that the previous meta-analysis might not fully demonstrate the efficacy of IC + CCRT in the treatment of NPC compared with CCRT. In order to minimize the bias, we selected prospective and clinical registered randomized controlled clinical trials as the eligible studies. Table 3Summary of the cited meta-analyses and this studySurvival outcomes^a^Total PatientsOSFFSDMFSLRFSChen 2015 \[[@CR17]\]206HR 0.70,95% CI 0.39--1.26FERR 0.51,95% CI 0.28--0.95RR 1.65,95% CI 0.95--2.86Song 2015 \[[@CR18]\]798HR 0.52,95% CI 0.21--1.29HR 0.66,95% CI 0.49--0.90HR 0.60,95% CI 0.39--0.98HR 0.66,95% CI 0.16--2.65Ouyang 2019 \[[@CR19]\]1418FEFEFEFEChen 2018 \[[@CR20]\]1193HR 0.75,95% CI 0.57--0.99HR 0.70,95% CI 0.56--0.86HR 0.68,95% CI 0.51--0.90HR 0.70,95% CI 0.48--1.01Tan 2018 \[[@CR21]\]2802HR 0.77,95% CI 0.60--0.98HR 0.69,95% CI 0.57--0.84HR 0.63,95% CI 0.47--0.83HR 0.66,95% CI 0.45--0.96Wang23113-year: HR 0.70,95% CI 0.55--0.89;5-year: HR 0.77,95% CI 0.62--0.943-year: HR 0.67,95% CI 0.55--0.80;5-year: HR 0.70,95% CI 0.58--0.833-year: HR 0.58,95% CI 0.45--0.74;5-year: HR 0.69,95% CI 0.55--0.873-year: HR 0.69,95% CI 0.50--0.95;5-year: HR 0.66,95% CI 0.51--0.86*OS* overall survival; *FFS* failure-free survival; *DMFS* distant metastasis-free survival; *LRFS* locoregional relapse-free survival; *HR* hazard ratio; 95% *CI* 95% confidence interval; *FE* fail to extract^a^ data of randomized clinical trials

Over 70% of newly diagnosed NPC patients were classified as locoregionally advanced diseases \[[@CR22]\]. Although IMRT combined with concurrent chemotherapy improved the locoregional control, long-term survival outcomes were poor. Distant recurrence might be a major reason for the treatment failure in long-term survived patients \[[@CR23]--[@CR25]\]. The efficacy of IC in the IC + CCRT group was due to the lower incidence of distant metastatic recurrence than that in the CCRT group. In Li's study, patients from the IC plus CCRT group showed significantly better 5-year DMFS 88% versus 79.8%; *p* = 0.030) \[[@CR11]\], while the corresponding figures reported by Yang et al. were 82.8% versus 73.1%, *p* = 0.014 \[[@CR13]\].

Patients could achieve better response rates and have longer survival outcomes with the administration of a more effective chemotherapeutic regimen. That is why the efficacy of IC plus CCRT in NPC is controversial \[[@CR26]--[@CR38]\]. A phase II randomized clinical study compared induction docetaxel + cisplatin plus CCRT against CCRT alone, indicating IC significantly increased 3-year OS, and positive effects on PFS and DMFS \[[@CR39]\]. However, another phase II clinical study showed that IC of cisplatin combined with paclitaxel and epirubicin followed with CCRT did not significantly improve OS and PFS compared with CCRT alone in NPC \[[@CR8]\]. Moreover, a randomized phase II-III study reported induction gemcitabine, carboplatin, and paclitaxel combined with CCRT had no significant differences in OS, disease-free survival (DFS) and DMFS compared with CCRT alone in patients with locoregionally advanced NPC \[[@CR9]\]. A previously prospective clinical study proved that gemcitabine combined with cisplatin might be better than fluorouracil plus cisplatin in the first-line treatment of recurrence/metastatic NPC \[[@CR40]\]. A retrospective study showed no significant difference in survival outcomes between induction cisplatin plus gemcitabine and cisplatin in combination with fluorouracil and docetaxel for the treatment of locoregionally advanced NPC \[[@CR41]\]. Several ongoing clinical studies might be leading to evaluate the benefit and risk of different induction chemotherapeutic regimens in patients with locoregionally advanced NPC. For instance, [NCT03604965](https://clinicaltrials.gov/ct2/show/NCT03604965), [NCT03503136](https://clinicaltrials.gov/ct2/show/NCT03503136), and [NCT02512315](https://clinicaltrials.gov/ct2/show/NCT02512315). The verification of the value of these treatment strategies is awaited.

Grade ≥ 3 adverse events were more frequent in the IC + CCRT group. During IC + CCRT, the most prominent grade ≥ 3 adverse events were neutropenia, thrombocytopenia, nausea, vomiting and hepatotoxicity. During CCRT, the most prominent grade 3 or more adverse events were thrombocytopenia, anemia and vomiting. However, these toxicities were uncomplicated, tolerated and manageable. We observed that there were no significant differences in radiotherapy related toxicities, comprising stomatitis (mucositis) and dermatitis, between the two groups. For late toxicities, Li et al. reported that the incidence of grade ≥ 3 late adverse events was 8.8% in the IC followed by CCRT group and 9.2% in the CCRT group \[[@CR11]\]. Yang's study also showed similar rates of late toxicities between IC + CCRT and CCRT alone group and auditory toxicities were the most common late adverse events \[[@CR13]\].

There are several limitations in this analysis. First, different regimens and cycles of IC and CCRT might influence the survival outcomes. Second, two/three-dimensional conformal radiotherapy (2D/3D-CRT) and intensity modulated radiotherapy (IMRT) were included in the studies. Although the advent of IMRT had been demonstrated to promote a higher local tumor control rate \[[@CR23]\], several studies had shown no significant advantage between 2D-CRT and IMRT in DMFS \[[@CR24]\]. Third, late adverse events data were limited for further analyses. Fourth, as the EBV is an important prognostic factor, in this meta-analysis, there is no important biomarker data to suggest that which group of patients based on EBV DNA level has benefited from IC plus CCRT as compared to CCRT alone. Li′s trial is the only study in this meta-analysis that performed post-hoc subgroup analysis and demonstrated that patients with EBV ≥ 6000 copies/ml had FFS benefit when received IC followed by CCRT as compared to CCRT \[[@CR11]\].

Conclusion {#Sec17}
==========

This systematic review and meta-analysis demonstrated that, compared with CCRT alone in patients with locoregionally advanced NPC, the addition of IC to CCRT achieved favorable survival rates, and could significantly improve survival outcomes, including OS, FFS, DMFS and LRFS. As the majority of eligible studies have taken place in endemic areas, the results might not be entirely applicable to patients in non-endemic regions (e.g. EBV- patients). Additionally, it should be further explored the best selection of patient subgroups who will get the most benefit from IC plus CCRT as well as the selection of the most effective regimens for induction chemotherapy.
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FE

:   Fail to extract
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